Long-term oncological outcomes after haemorrhagic apoplexy in pituitary adenoma managed operatively and non-operatively.


Journal

Acta neurochirurgica
ISSN: 0942-0940
Titre abrégé: Acta Neurochir (Wien)
Pays: Austria
ID NLM: 0151000

Informations de publication

Date de publication:
04 2022
Historique:
received: 26 09 2021
accepted: 03 12 2021
pubmed: 19 1 2022
medline: 2 4 2022
entrez: 18 1 2022
Statut: ppublish

Résumé

Depending on severity of presentation, pituitary apoplexy can be managed with acute surgery or non-operatively. We aim to assess long-term tumour control, visual and endocrinological outcomes following pituitary apoplexy with special emphasis on patients treated non-operatively. Multicentre retrospective cohort study. All patients with symptomatic pituitary apoplexy were included. Patients were divided into 3 groups: group 1: surgery within 7 days; group 2: surgery 7 days-3 months; group 3: non-operative. Further intervention for oncological reasons during follow-up was the primary outcome. Secondary outcome measures included visual and endocrinological function at last follow-up. One hundred sixty patients were identified with mean follow-up of 48 months (n = 61 group 1; n = 34 group 2; n = 64 group 3). Factors influencing decision for surgical treatment included visual acuity loss (OR: 2.50; 95% CI: 1.02-6.10), oculomotor nerve palsy (OR: 2.80; 95% CI: 1.08-7.25) and compression of chiasm on imaging (OR: 9.50; 95% CI: 2.06-43.73). Treatment for tumour progression/recurrence was required in 17%, 37% and 24% in groups 1, 2 and 3, respectively (p = 0.07). Urgent surgery (OR: 0.16; 95% CI: 0.04-0.59) and tumour regression on follow-up (OR: 0.04; 95% CI: 0.04-0.36) were independently associated with long-term tumour control. Visual and endocrinological outcomes were comparable between groups. Urgent surgery is an independent predictor of long-term tumour control following pituitary apoplexy. However, 76% of patients who successfully complete 3 months of non-operative treatment may not require any intervention in the long term.

Identifiants

pubmed: 35039959
doi: 10.1007/s00701-022-05119-8
pii: 10.1007/s00701-022-05119-8
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1115-1123

Subventions

Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

© 2022. Crown.

Références

Almeida JP, Sanchez MM, Karekezi C et al (2019) Pituitary apoplexy: results of surgical and conservative management clinical series and review of the literature. World Neurosurg 130:e988–e999
doi: 10.1016/j.wneu.2019.07.055
Arafah BM, Harrington JF, Madhoun ZT, Selman WR (1990) Improvement of pituitary function after surgical decompression for pituitary tumor apoplexy. J Clin Endocrinol Metab 71(2):323–328
doi: 10.1210/jcem-71-2-323
Armstrong MR, Douek M, Schellinger D, Patronas NJ (1991) Regression of pituitary macroadenoma after pituitary apoplexy. J Comput Assist Tomogr 15(5):832–834
doi: 10.1097/00004728-199109000-00021
Ayuk J, McGregor EJ, Mitchell RD, Gittoes NJL (2004) Acute management of pituitary apoplexy—surgery or conservative management? Clin Endocrinol (Oxf) 61(6):747–752
doi: 10.1111/j.1365-2265.2004.02162.x
Bills DC, Meyer FB, Laws ER, Davis DH, Ebersold MJ, Scheithauer BW, Ilstrup DM, Abboud CF (1993) A retrospective analysis of pituitary apoplexy. Neurosurgery 33(4):602–8; discussion 608–9
Bonicki W, Kasperlik-Załuska A, Koszewski W, Zgliczyński W, Wisławski J (1993) Pituitary apoplexy: endocrine, surgical and oncological emergency. Incidence, clinical course and treatment with reference to 799 cases of pituitary adenomas. Acta Neurochir (Wien) 120(3–4):118–22
Bujawansa S, Thondam SK, Steele C, Cuthbertson DJ, Gilkes CE, Noonan C, Bleaney CW, MacFarlane IA, Javadpour M, Daousi C (2014) Presentation, management and outcomes in acute pituitary apoplexy: a large single-centre experience from the United Kingdom. Clin Endocrinol (Oxf) 80(3):419–424
doi: 10.1111/cen.12307
Dubuisson AS, Beckers A, Stevenaert A (2007) Classical pituitary tumour apoplexy: clinical features, management and outcomes in a series of 24 patients. Clin Neurol Neurosurg 109(1):63–70
doi: 10.1016/j.clineuro.2006.01.006
Giritharan S, Gnanalingham K, Kearney T (2016) Pituitary apoplexy—bespoke patient management allows good clinical outcome. Clin Endocrinol (Oxf) 85(3):415–422
doi: 10.1111/cen.13075
Goshtasbi K, Abiri A, Sahyouni R, Mahboubi H, Raefsky S, Kuan EC, Hsu FPK, Cadena G (2019) Visual and endocrine recovery following conservative and surgical treatment of pituitary apoplexy: a meta-analysis. World Neurosurg 132:33–40
doi: 10.1016/j.wneu.2019.08.115
Gruber A, Clayton J, Kumar S, Robertson I, Howlett T, Mansell P (2006) Pituitary apoplexy: retrospective review of 30 patients—is surgical intervention always necessary? Br J Neurosurg. https://doi.org/10.1080/02688690601046678
doi: 10.1080/02688690601046678 pubmed: 17439089
Maccagnan P, Macedo CL, Kayath MJ, Nogueira RG, Abucham J (1995) Conservative management of pituitary apoplexy: a prospective study. J Clin Endocrinol Metab 80(7):2190–2197
pubmed: 7608278
Pangal DJ, Chesney K, Memel Z, Bonney PA, Strickland BA, Carmichael J, Shiroishi M, Jason Liu CS, Zada G (2020) Pituitary apoplexy case series: outcomes after endoscopic endonasal transsphenoidal surgery at a single tertiary center. World Neurosurg 1–7
Patel HC, Bouamra O, Woodford M, King AT, Yates DW, Lecky FE (2005) Trends in head injury outcome from 1989 to 2003 and the effect of neurosurgical care: an observational study. Lancet 366(9496):1538–1544
doi: 10.1016/S0140-6736(05)67626-X
Rajasekaran S, Vanderpump M, Baldeweg S, et al (2011) UK guidelines for the management of pituitary apoplexy. Pituitary Apoplexy Guidelines Development Group: May 2010. Clin Endocrinol (Oxf) 74(1):9–20
Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CBT, Wass JAH (1999) Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxf) 51(2):181–188
doi: 10.1046/j.1365-2265.1999.00754.x
Reddy NL, Rajasekaran S, Han TS, Theodoraki A, Drake W, Vanderpump M, Baldeweg S, Wass JAH (2011) An objective scoring tool in the management of patients with pituitary apoplexy. Clin Endocrinol (Oxf) 75(5):723
doi: 10.1111/j.1365-2265.2011.04081.x
Rutkowski MJ, Kunwar S, Blevins L, Aghi MK (2018) Surgical intervention for pituitary apoplexy: an analysis of functional outcomes. J Neurosurg 129(2):417–424
doi: 10.3171/2017.2.JNS1784
Seuk J-W, Kim C-H, Yang M-S, Cheong J-H, Kim J-M (2011) Visual outcome after transsphenoidal surgery in patients with pituitary apoplexy. J Korean Neurosurg Soc 49(6):339
doi: 10.3340/jkns.2011.49.6.339
Sibal L, Ball SG, Connolly V et al (2004) Pituitary apoplexy: a review of clinical presentation, management and outcome in 45 cases. Pituitary 7(3):157–163
doi: 10.1007/s11102-005-1050-3
Singh TD, Valizadeh N, Meyer FB, Atkinson JLD, Erickson D, Rabinstein AA (2015) Management and outcomes of pituitary apoplexy. J Neurosurg 122(6):1450–1457
doi: 10.3171/2014.10.JNS141204
Tu M, Lu Q, Zhu P, Zheng W (2016) Surgical versus non-surgical treatment for pituitary apoplexy: a systematic review and meta-analysis. J Neurol Sci 370:258–262
doi: 10.1016/j.jns.2016.09.047
Woo H-J, Hwang J-H, Hwang S-K, Park Y-M (2010) Clinical outcome of cranial neuropathy in patients with pituitary apoplexy. J Korean Neurosurg Soc 48(3):213–218
doi: 10.3340/jkns.2010.48.3.213
Zhang X, Fei Z, Zhang W et al (2007) Emergency transsphenoidal surgery for hemorrhagic pituitary adenomas. Surg Oncol 16(2):115–120
doi: 10.1016/j.suronc.2007.06.001
Zieliński G, Witek P, Koziarski A, Podgórski J (2013) Spontaneous regression of non-functioning pituitary adenoma due to pituitary apoplexy following anticoagulation treatment—a case report and review of the literature. Endokrynol Pol 64(1):54–58
pubmed: 23450448

Auteurs

Karol P Budohoski (KP)

Department of Neurosurgery, Cambridge University Hospitals, Cambridge, UK.

Sogha Khawari (S)

Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, London, UK. sogha.khawari@nhs.net.

Andrea Cavalli (A)

Department of Neurosurgery, Royal Hallamshire Hospital, Sheffield, UK.

Boon L Quah (BL)

Department of Neurosurgery, Manchester Centre for Clinical Neurosciences, Salford Royal Hospital, Manchester, UK.

Angelos Kolias (A)

Department of Neurosurgery, Cambridge University Hospitals, Cambridge, UK.

Mueez Waqar (M)

Department of Neurosurgery, Manchester Centre for Clinical Neurosciences, Salford Royal Hospital, Manchester, UK.

Prahlad G Krishnan (PG)

Department of Neurosurgery, Cambridge University Hospitals, Cambridge, UK.

Indu Lawes (I)

Department of Neurosurgery, Cambridge University Hospitals, Cambridge, UK.

Fiona Cains (F)

Department of Neurosurgery, Manchester Centre for Clinical Neurosciences, Salford Royal Hospital, Manchester, UK.

James Arwyn-Jones (J)

Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, London, UK.

Zhangjie Su (Z)

Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, London, UK.

Mark Gurnell (M)

Department of Endocrinology, Cambridge University Hospitals, Cambridge, UK.

Andrew Powlson (A)

Department of Endocrinology, Cambridge University Hospitals, Cambridge, UK.

Neil Donnelly (N)

Department of Otoloaryngology and Skull Base Surgery, Cambridge University Hospitals, Cambridge, UK.

James Tysome (J)

Department of Otoloaryngology and Skull Base Surgery, Cambridge University Hospitals, Cambridge, UK.

Rishi Sharma (R)

Department of Otoloaryngology and Skull Base Surgery, Cambridge University Hospitals, Cambridge, UK.

Brinda Muthusamy (B)

Department of Ophthalmology, Cambridge University Hospitals, Cambridge, UK.

Tara Kearney (T)

Department of Endocrinology, Salford Royal Hospital, Manchester, UK.

Adam Robinson (A)

Department of Endocrinology, Salford Royal Hospital, Manchester, UK.

Hani J Marcus (HJ)

Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, London, UK.

Kanna Gnanalingham (K)

Department of Neurosurgery, Manchester Centre for Clinical Neurosciences, Salford Royal Hospital, Manchester, UK.

Konstantina Karabatsou (K)

Department of Neurosurgery, Manchester Centre for Clinical Neurosciences, Salford Royal Hospital, Manchester, UK.

Omar N Pathmanaban (ON)

Department of Neurosurgery, Manchester Centre for Clinical Neurosciences, Salford Royal Hospital, Manchester, UK.

Saurabh Sinha (S)

Department of Neurosurgery, Royal Hallamshire Hospital, Sheffield, UK.

Thomas Santarius (T)

Department of Neurosurgery, Cambridge University Hospitals, Cambridge, UK.

Richard Mannion (R)

Department of Neurosurgery, Cambridge University Hospitals, Cambridge, UK.

Ramez W Kirollos (RW)

Geoffrey Jefferson Brain Research Centre, University of Manchester, Manchester, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH